Grifols SA Signals Resilient Growth in Latest Earnings Call

Grifols SA ((GRFS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Grifols SA’s latest earnings call painted a cautiously upbeat picture, with management emphasizing solid revenue growth, resilient margins and improving profitability despite clear pockets of softness. Investors heard a story of stronger Biopharma momentum, tighter cost control and a fortified balance sheet, even as near-term pressures in China, certain specialty products and FX translation weighed on reported figures.

Revenue Growth Holds Up Despite Currency Drag

Grifols reported Q1 2026 revenue of EUR 1.7 billion, up 3.3% at constant currency versus a year earlier, underscoring steady top-line momentum. Reported growth in euros was dampened by a weaker U.S. dollar, but underlying demand trends remained broadly supportive across the portfolio.

EBITDA Stability Underscores Margin Resilience

Adjusted EBITDA reached EUR 381 million, or EUR 404 million at constant currency, with the margin holding around 22.4% and growing 0.8% in constant terms. Management highlighted that disciplined execution and cost actions largely offset inflationary and FX pressures, preserving profitability.

Biopharma Strength Led by Immunoglobulins

Biopharma revenue climbed 6.8% at constant currency, driven by robust demand for immunoglobulins. IG sales surged 15.3% year-on-year, supported by strong Gamunex performance and double-digit growth from Xembify, which is expected to maintain strong double-digit gains for the full year.

Profitability and Bottom Line Improve

Group profit rose 22% year-over-year to EUR 73 million in Q1 2026, despite FX translation headwinds. The improvement reflected operating leverage, cost discipline and a healthier product mix, signaling that earnings quality is improving as the company executes its plan.

OpEx Cuts Showcase Cost Discipline

Operating expenses fell 7.7% at constant currency versus Q1 2025, providing an important buffer for margins. Management framed these reductions as structural efficiency gains rather than short-term cuts, suggesting further upside to profitability as volumes grow.

Balance Sheet and Liquidity Get a Boost

Net leverage improved to 4.3x, down 0.2 turns from a year ago, aided by higher EBITDA and balance-sheet actions. The group refinanced key liabilities, eliminated near-term 2027 maturities and expanded its revolving facility to more than $2 billion with a 6.5-year term, reducing refinancing risk until late 2028.

Debt Structure and Credit Profile Strengthen

Grifols executed a partial redemption of EUR 500 million of 7.5% bonds, taking advantage of strong investor demand to improve its capital structure. Two of three rating agencies upgraded the company back into the BB range, signaling improved confidence in its credit quality and financial trajectory.

Egypt Plasma Sourcing: Strategic Cost Lever

The company secured EMA approval for plasma sourced from Egypt and plans to collect around 1 million liters there in 2026, ramping to about 3 million liters by 2029. Management expects ex-U.S. plasma volumes to increase roughly 2.5 times over that period, a shift that should lower cost per liter and support margin expansion.

Diagnostics Strategy and Future Platforms

On a like-for-like basis, excluding the impact of dissolving its Diagnostics joint venture, Grifols delivered low single-digit growth in the segment. The company will receive compensation over three years and is preparing to launch its Barcelona Next Generation blood-typing system and ISARD immunoassay platform, aimed at expanding its addressable market.

Productivity Gains from Network Optimization

To improve efficiency, Grifols closed or optimized 29 underperforming U.S. donor centers, consolidating volume into better-performing sites. Management expects this to enhance network quality and lower plasma cost per liter over time, without requiring significant new industrial capital.

Albumin Weakness in China Weighs on Growth

Albumin revenue declined 6.1% at constant currency in Q1, mainly due to pricing pressure, high inventories in China and mid-2025 price adjustments. The company warned that the first half will remain challenging versus last year but expects conditions to stabilize into the second half of 2026.

Alpha-1 and Specialty Proteins Under Pressure

Alpha-1 and specialty proteins revenues fell 7.4% year-on-year, dragged by a tough comparison with prior-year inventory buy-ins and softer sales of fibrin sealant and Factor VIII. Access and reauthorization hurdles in the U.S. also weighed on volumes, though management framed these issues as manageable and working through the system.

Diagnostics Reporting Hit by JV Exit

Reported Diagnostics revenue declined due to the dissolution of the Quidel Ortho joint venture, masking underlying growth in the low single digits. While the near-term reporting impact is negative, compensation over three years and the move to a more autonomous Diagnostics strategy should help offset the headwind.

Seasonally Weak but Improving Free Cash Flow

Free cash flow before M&A was slightly negative at EUR 8 million in the quarter, although this represented a EUR 30 million improvement versus Q1 2025. The shortfall was mainly driven by inventory builds to support rising demand, a seasonal pattern management expects to reverse as the year progresses.

FX Headwinds Cloud Reported Results

The weakening U.S. dollar, with the EUR/USD average moving from 1.04 to 1.18 year-over-year, weighed on reported revenue and EBITDA. Some of this impact was offset further down the income statement, but it still diluted euro-reported growth relative to the stronger constant-currency performance.

Bio Supplies Variability from Contract Timing

Bio Supplies and other businesses posted lower revenues in Q1, largely due to contract phasing and spot-deal timing. Management guided that this segment should see a catch-up in the second half, particularly in the third and fourth quarters, making the Q1 softness appear more timing-related than structural.

Commercial and Access Challenges Persist

The company acknowledged ongoing commercialization hurdles in both the U.S. and China, including reauthorization issues affecting Alpha-1 patients and competitive pricing pressure in some categories. Albumin and selected specialty products are expected to remain under strain in the first half as these dynamics play out.

IPO Uncertainty Creates Investor Overhang

Grifols confirmed it is evaluating a possible initial public offering of a portion of its U.S. Biopharma business but offered no timeline or details. The lack of visibility around this potential transaction introduces an element of uncertainty for investors, even as management underscores its strategic optionality.

Forward Guidance Emphasizes Margin and Cash Gains

Management reiterated its 2026 targets, including an adjusted EBITDA margin of at least 25%, constant-currency EBITDA growth of 5–9% and improving free cash flow toward EUR 500–575 million. They pointed to Q1’s 3.3% constant-currency revenue growth, stable 22.4% EBITDA margin, improving free cash flow and lower leverage as evidence that the plan is on track, while expecting continued growth from key IG products and further benefits from plasma and cost initiatives.

Grifols’ earnings call ultimately balanced clear operational progress against localized pressures in China, certain specialties and FX. For investors, the message was that Biopharma momentum, margin resilience and a stronger balance sheet are starting to outweigh the drag from albumin, Diagnostics reporting noise and seasonal cash use, leaving the company better positioned for the rest of 2026.